Rydapt (Midostaurin) Patent Expiration, LOE Window & CMS Spending
Rydapt (Midostaurin) by Novartis: FDA Orange Book LOE 2030-12-02, 2 AB generics, $35.8M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N207997 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2030-12-02 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $35.8M |
| 2024 Medicare Part D Spend | $27.4M |
| 2024 Medicaid Spend | $8.4M |
| Reported Wholesale Price Change (CA SB 17) | 8 WAC filings (max 24.4% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.